Distinguished in Head and Neck Squamous Cell Carcinoma (HNSCC)

Dr. Mitchell X. Machtay

Radiation Oncology
The Milton S Hershey Medical Center Physicians Group
500 University Dr, 
Hershey, PA 
Clinical Trials:Currently Recruiting for 2 Trials
Distinguished in Head and Neck Squamous Cell Carcinoma (HNSCC)
The Milton S Hershey Medical Center Physicians Group
500 University Dr, 
Hershey, PA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Mitchell Machtay is a Radiation Oncologist in Hershey, Pennsylvania. Dr. Machtay is rated as a Distinguished provider by MediFind in the treatment of Head and Neck Squamous Cell Carcinoma (HNSCC). His top areas of expertise are Lung Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and Gamma Knife Radiosurgery.

His clinical research consists of co-authoring 129 peer reviewed articles and participating in 19 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 11 articles and participated in 2 clinical trials in the study of Head and Neck Squamous Cell Carcinoma (HNSCC).

Specialties
Radiation Oncology
Licenses
Radiology in OH
Hospital Affiliations
Milton S Hershey Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Cigna
  • EPO
  • HMO
  • PPO
Gateway Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • OTHER MEDICARE PART D
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
PA Health and Wellness
  • HMO
  • MANAGED MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 4 Less Insurance Carriers -

Locations

THE MILTON S HERSHEY MEDICAL CENTER PHYSICIANS GROUP
500 University Dr, Hershey, PA 17033

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

19 Clinical Trials

Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Enrollment Status: Recruiting
Publish Date: October 14, 2025
Intervention Type: Procedure, Drug, Other, Radiation, Biological
Study Drugs: Atezolizumab, Cetuximab, Cisplatin, Docetaxel
Study Phase: Phase 2/Phase 3
Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma
Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma
Enrollment Status: Recruiting
Publish Date: September 08, 2025
Intervention Type: Other, Procedure, Radiation
Study Phase: Phase 3
A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC
A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC
Enrollment Status: Suspended
Publish Date: October 10, 2025
Intervention Type: Procedure, Drug, Biological, Radiation, Other
Study Drugs: Cisplatin, Nivolumab
Study Phase: Phase 3
A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Other, Procedure, Drug, Biological, Radiation
Study Drugs: Cisplatin, Nivolumab
Study Phase: Phase 2/Phase 3
Phase 1 Trial to Determine the Recommended Phase 2 Dose (RP2D) of M6620 (VX-970, Berzosertib) When Combined With Whole Brain Radiotherapy (WBRT) in Patients With Brain Metastases From Lung Cancer
Phase 1 Trial to Determine the Recommended Phase 2 Dose (RP2D) of M6620 (VX-970, Berzosertib) When Combined With Whole Brain Radiotherapy (WBRT) in Patients With Brain Metastases From Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 08, 2025
Intervention Type: Other, Radiation, Drug, Procedure
Study Drug: Berzosertib
Study Phase: Phase 1
Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Radiation, Drug
Study Drug: Temozolomide
Study Phase: Phase 2
A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (BALANCE*)
A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (BALANCE*)
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2025
Intervention Type: Other, Radiation, Drug
Study Drug: Apalutamide
Study Phase: Phase 2
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Enrollment Status: Active_not_recruiting
Publish Date: September 02, 2025
Intervention Type: Other, Drug, Radiation, Procedure
Study Drugs: Atezolizumab, Carboplatin, Cisplatin, Etoposide
Study Phase: Phase 3
A Randomized Phase III Trial of Memantine and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Patients With Brain Metastases
A Randomized Phase III Trial of Memantine and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Patients With Brain Metastases
Enrollment Status: Completed
Publish Date: April 23, 2025
Intervention Type: Radiation, Drug
Study Phase: Phase 3
Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
Enrollment Status: Active_not_recruiting
Publish Date: March 11, 2025
Intervention Type: Radiation, Drug
Study Drugs: Docetaxel, Gemcitabine, Pemetrexed Disodium, Erlotinib Hydrochloride, Pembrolizumab
Study Phase: Phase 2
Randomized Phase II/III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer
Randomized Phase II/III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 17, 2024
Intervention Type: Radiation
Study Phase: Phase 2/Phase 3
GRECO-2: A Randomized, Phase 2b Study of GC4711 in Combination With Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Unresectable or Borderline Resectable Nonmetastatic Pancreatic Cancer
GRECO-2: A Randomized, Phase 2b Study of GC4711 in Combination With Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Unresectable or Borderline Resectable Nonmetastatic Pancreatic Cancer
Enrollment Status: Terminated
Publish Date: May 21, 2024
Intervention Type: Drug
Study Drug: Drug GC4711
Study Phase: Phase 2
Magnetic Resonance Guided Focal Stereotactic Body Radiation Therapy for Localized Prostate Cancer
Magnetic Resonance Guided Focal Stereotactic Body Radiation Therapy for Localized Prostate Cancer
Enrollment Status: Completed
Publish Date: May 10, 2024
Intervention Type: Radiation, Device, Behavioral, Other, Procedure
Study Phase: Not Applicable
A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer
A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer
Enrollment Status: Completed
Publish Date: April 24, 2024
Intervention Type: Drug, Radiation, Biological
Study Phase: Phase 2
A Pilot Trial of Proton Based Cardiac Sparing Accelerated Fractionated RadioTherapy in Unresectable Non-Small Cell Lung Cancer With Extended Durvalumab Therapy (PARTICLE-D)
A Pilot Trial of Proton Based Cardiac Sparing Accelerated Fractionated RadioTherapy in Unresectable Non-Small Cell Lung Cancer With Extended Durvalumab Therapy (PARTICLE-D)
Enrollment Status: Terminated
Publish Date: February 15, 2024
Intervention Type: Drug, Radiation
Study Drug: Durvalumab
Study Phase: Early Phase 1
Phase II Randomized Study of Whole Brain Radiotherapy/Stereotactic Radiosurgery in Combination With Concurrent Lapatinib in Patients With Brain Metastasis From HER2-Positive Breast Cancer - A Collaborative Study of NRG Oncology and KROG
Phase II Randomized Study of Whole Brain Radiotherapy/Stereotactic Radiosurgery in Combination With Concurrent Lapatinib in Patients With Brain Metastasis From HER2-Positive Breast Cancer - A Collaborative Study of NRG Oncology and KROG
Enrollment Status: Completed
Publish Date: October 17, 2023
Intervention Type: Other, Radiation, Drug
Study Drug: Lapatinib Ditosylate
Study Phase: Phase 2
A Phase 1 Study of Trametinib in Combination With Chemoradiation for KRAS Mutant Non-small Cell Lung Cancer
A Phase 1 Study of Trametinib in Combination With Chemoradiation for KRAS Mutant Non-small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: May 06, 2023
Intervention Type: Radiation, Drug, Other
Study Drugs: Carboplatin, Paclitaxel, Trametinib
Study Phase: Phase 1
Pilot Study Evaluating the Role of Histopathology Correlation in Treatment Planning
Pilot Study Evaluating the Role of Histopathology Correlation in Treatment Planning
Enrollment Status: Completed
Publish Date: June 30, 2022
Intervention Type: Device
Study Phase: Not Applicable
Randomized Phase II Trial of Individualized Adaptive Radiotherapy Using During-Treatment FDG-PET/CT and Modern Technology in Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
Randomized Phase II Trial of Individualized Adaptive Radiotherapy Using During-Treatment FDG-PET/CT and Modern Technology in Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Unknown
Publish Date: April 29, 2021
Intervention Type: Drug, Procedure, Radiation, Other
Study Drugs: 18F-Fluoromisonidazole, Carboplatin, Fludeoxyglucose F-18, Paclitaxel
Study Phase: Phase 2
View 17 Less Clinical Trials

129 Total Publications

Author Correction: Stereotactic radiosurgery for patients with brain metastases: current principles, expanding indications and opportunities for multidisciplinary care.
Author Correction: Stereotactic radiosurgery for patients with brain metastases: current principles, expanding indications and opportunities for multidisciplinary care.
Journal: Nature reviews. Clinical oncology
Published: October 03, 2025
Similar Doctors
David C. Weksberg
Advanced in Head and Neck Squamous Cell Carcinoma (HNSCC)
Dr. David C. Weksberg
Radiation Oncology
Advanced in Head and Neck Squamous Cell Carcinoma (HNSCC)
Dr. David C. Weksberg
Radiation Oncology

UPMC Hillman Cancer Center At Rocco And Nancy Ortenzio Cancer Pavilion

2035 Technology Parkway, 
Mechanicsburg, PA 
 (15.8 miles away)
717-988-1400
Languages Spoken:
English
See accepted insurances
Accepting New Patients

David Weksberg, MD, specializes in radiation oncology and is board-certified by the American Board of Radiology. He is affiliated with UPMC West Shore, UPMC Community Osteopathic, UPMC Harrisburg, UPMC Carlisle, UPMC Lititz, UPMC Memorial, and UPMC Altoona. Dr. Weksberg received his medical degree from Baylor College of Medicine and completed his residency at the University of Texas MD Anderson Cancer Center. Dr. Weksberg is rated as an Advanced provider by MediFind in the treatment of Head and Neck Squamous Cell Carcinoma (HNSCC). His top areas of expertise are Pleuropulmonary Blastoma, Lung Cancer, Laryngeal Cancer, and Small Cell Lung Cancer (SCLC).

Advanced in Head and Neck Squamous Cell Carcinoma (HNSCC)
Dr. Ori Shokek
Radiation Oncology
Advanced in Head and Neck Squamous Cell Carcinoma (HNSCC)
Dr. Ori Shokek
Radiation Oncology

Wellspan Medical Group

25 Monument Rd, 
York, PA 
 (23.5 miles away)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ori Shokek is a Radiation Oncologist in York, Pennsylvania. Dr. Shokek is rated as an Advanced provider by MediFind in the treatment of Head and Neck Squamous Cell Carcinoma (HNSCC). His top areas of expertise are Familial Prostate Cancer, Pleuropulmonary Blastoma, Lung Cancer, and Pineocytoma.

Advanced in Head and Neck Squamous Cell Carcinoma (HNSCC)
Dr. Bradley A. Kramer
Radiation Oncology
Advanced in Head and Neck Squamous Cell Carcinoma (HNSCC)
Dr. Bradley A. Kramer
Radiation Oncology

Geisinger Clinic

75 Medical Park Dr, 
Lewisburg, PA 
 (50.7 miles away)
570-523-9200
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Bradley Kramer is a Radiation Oncologist in Lewisburg, Pennsylvania. Dr. Kramer is rated as an Advanced provider by MediFind in the treatment of Head and Neck Squamous Cell Carcinoma (HNSCC). His top areas of expertise are Head and Neck Squamous Cell Carcinoma (HNSCC), Breast Cancer, Prostate Cancer, and Familial Prostate Cancer. Dr. Kramer is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Machtay's expertise for a condition
ConditionClose
    View All 7 Distinguished Conditions
    View All 7 Advanced Conditions
    View All 29 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile